Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2

Abstract

The establishment of functional and stable vascular networks is essential for angiogenic therapy. Here we report that a combination of two angiogenic factors, platelet-derived growth factor (PDGF)-BB and fibroblast growth factor (FGF)-2, synergistically induces vascular networks, which remain stable for more than a year even after depletion of angiogenic factors. In both rat and rabbit ischemic hind limb models, PDGF-BB and FGF-2 together markedly stimulated collateral arteriogenesis after ligation of the femoral artery, with a significant increase in vascularization and improvement in paw blood flow. A possible mechanism of angiogenic synergism between PDGF-BB and FGF-2 involves upregulation of the expression of PDGF receptor (PDGFR)-alpha and PDGFR-beta by FGF-2 in newly formed blood vessels. Our data show that a specific combination of angiogenic factors establishes functional and stable vascular networks, and provides guidance for the ongoing clinical trials of angiogenic factors for the treatment of ischemic diseases.

Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer

“…3E). The secretion of FGF2 has been mainly attributed to cancer cells (27,29), we showed the existence of an autocrine loop ECs to bevacizumab treatment. Escalating doses of neutralizing agent were tested concomitant to bevacizumab treatment (1.5 mg/mL).…”

“…S4D). Additional angiogenic factors such as FGF2 (26) can compensate the blockade of VEGF (27). Interestingly, transcriptomic and RT-PCR analysis showed that FGFR1 mRNA was increased by 2.5-fold in E4 þ ECs compared with HUVECs (Supplementary Fig.…”

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

“…However, further investigation is required to solve mayor problems that are critical to successful therapy: identification of the most effective delivery approach, proper selection of patients, timing and dosage of angiogenic factors used alone or in combinations [248]. …”

Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action

“…Fibroblast growth factor (FGF)-2 and -4 were inhibited significantly by PNB-028. Literature evidences suggest that FGF is a highly potent angiogenic growth factor with FGF-2 being more potent than even vascular endothelial growth factor (VEGF) (35). Another important growth factor responsible for angiogenesis and cancer cell proliferation, fGf-4, was also significantly inhibited by PnB-028 (36).…”